These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 34244999)
1. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. Korecka M; Shaw LM J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999 [TBL] [Abstract][Full Text] [Related]
2. Biomarkers for Alzheimer's disease: current status and prospects for the future. Blennow K; Zetterberg H J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512 [TBL] [Abstract][Full Text] [Related]
3. Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease. Pottiez G; Yang L; Stewart T; Song N; Aro P; Galasko DR; Quinn JF; Peskind ER; Shi M; Zhang J J Proteome Res; 2017 Mar; 16(3):1228-1238. PubMed ID: 28112948 [TBL] [Abstract][Full Text] [Related]
4. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R; Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606 [TBL] [Abstract][Full Text] [Related]
5. Brain-related proteins as potential CSF biomarkers of Alzheimer's disease: A targeted mass spectrometry approach. Begcevic I; Brinc D; Brown M; Martinez-Morillo E; Goldhardt O; Grimmer T; Magdolen V; Batruch I; Diamandis EP J Proteomics; 2018 Jun; 182():12-20. PubMed ID: 29684683 [TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Wang H; Dey KK; Chen PC; Li Y; Niu M; Cho JH; Wang X; Bai B; Jiao Y; Chepyala SR; Haroutunian V; Zhang B; Beach TG; Peng J Mol Neurodegener; 2020 Jul; 15(1):43. PubMed ID: 32711556 [TBL] [Abstract][Full Text] [Related]
7. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers. Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806 [TBL] [Abstract][Full Text] [Related]
12. Direct coupling of fiber-in-tube solid-phase microextraction with tandem mass spectrometry to determine amyloid beta peptides as biomarkers for Alzheimer's disease in cerebrospinal fluid samples. Souza ID; Anderson JL; Tumas V; Queiroz MEC Talanta; 2023 Mar; 254():124186. PubMed ID: 36521326 [TBL] [Abstract][Full Text] [Related]
13. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease. Robinson RA; Amin B; Guest PC Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies. Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009 [TBL] [Abstract][Full Text] [Related]
15. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Blennow K; Zetterberg H Prog Mol Biol Transl Sci; 2019; 168():3-23. PubMed ID: 31699324 [TBL] [Abstract][Full Text] [Related]
16. Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease. Aluise CD; Sowell RA; Butterfield DA Biochim Biophys Acta; 2008 Oct; 1782(10):549-58. PubMed ID: 18760351 [TBL] [Abstract][Full Text] [Related]
19. Peptide fingerprinting of Alzheimer's disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers. Jahn H; Wittke S; Zürbig P; Raedler TJ; Arlt S; Kellmann M; Mullen W; Eichenlaub M; Mischak H; Wiedemann K PLoS One; 2011; 6(10):e26540. PubMed ID: 22046305 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers in Alzheimer's disease analysis by mass spectrometry-based proteomics. Liu Y; Qing H; Deng Y Int J Mol Sci; 2014 May; 15(5):7865-82. PubMed ID: 24806343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]